Compare Roblox Corp (RBLX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Tango Therapeutics Inc. — how do they compare? Roblox Corp trades at $46.91 (market cap $35.37B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Roblox Corp is far larger — about 9.4× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 94 Days and Tango Therapeutics Inc. for 0 Days on average.
| RBLX | TNGX | |
|---|---|---|
Market Cap | $35.37B | $3.75B |
Volume | 6,569,814 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $138.56 | $32.90 |
52-Week Low | $35.54 | $7.50 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $34.19B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $47.54, down 4.13% today amid mixed technical signals and analyst concerns about bookings growth. The stock shows strong revenue growth (2025: $4.89B, up 36% year-over-year) but remains unprofitable with a -17.61% net margin. Recent technical analysis indicates bullish moving averages but neutral oscillators, with key resistance at $50-$52. The company continues to beat earnings expectations, with Q2 2026 EPS of -$0.26 beating estimates by 24%.
Investment outlook balances strong user engagement and AI-driven creator tools against persistent profitability challenges. Analyst consensus sits at $51.35 with 42% buy ratings, though recent Jefferies downgrade to Underperform highlights concerns about valuation sustainability. Key risks include decelerating bookings growth and high P/B ratio of 232.69, while opportunities lie in AI-powered platform expansion and $3 billion buyback program.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
